These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 17350337)

  • 1. Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre.
    Webster-Gandy JD; How C; Harrold K
    Eur J Oncol Nurs; 2007 Jul; 11(3):238-46. PubMed ID: 17350337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The hand-foot syndrome--a frequent secondary manifestation in antineoplastic chemotherapy.
    Janusch M; Fischer M; Marsch WCh; Holzhausen HJ; Kegel T; Helmbold P
    Eur J Dermatol; 2006; 16(5):494-9. PubMed ID: 17101468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Plantar-palmar erythrodysesthesia. A new and relatively frequent side effect in antineoplastic treatment].
    Risum S; Langer SW
    Ugeskr Laeger; 2003 Aug; 165(33):3161-2. PubMed ID: 12968412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
    Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK
    Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda).
    Lassere Y; Hoff P
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S31-40. PubMed ID: 15341880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated body mass index does not increase the risk of palmar-plantar erythrodysesthesia in patients receiving pegylated liposomal doxorubicin.
    Gordinier ME; Dizon DS; Fleming EL; Weitzen S; Schwartz J; Parker LP; Granai CO
    Gynecol Oncol; 2006 Oct; 103(1):72-4. PubMed ID: 16494932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts.
    von Moos R; Thuerlimann BJ; Aapro M; Rayson D; Harrold K; Sehouli J; Scotte F; Lorusso D; Dummer R; Lacouture ME; Lademann J; Hauschild A
    Eur J Cancer; 2008 Apr; 44(6):781-90. PubMed ID: 18331788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management.
    Nagore E; Insa A; Sanmartín O
    Am J Clin Dermatol; 2000; 1(4):225-34. PubMed ID: 11702367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy-induced palmer planter erythrodysesthesia.
    Bhasin S; Sunita ; Gupta DK; Kataria SP; Saluja S; Sharma M
    J Assoc Physicians India; 2005 Feb; 53():155-6. PubMed ID: 15847041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Grade 3 liposomal-doxorubicin-induced skin toxicity in a patient following complete resolution of moderately severe sunburn.
    Markman M; Kulp B; Peterson G
    Gynecol Oncol; 2004 Aug; 94(2):578-80. PubMed ID: 15297208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Main treatment and preventive measures for hand-foot syndrome, a dermatologic side effect of cancer therapy].
    Bartal A; Mátrai Z; Szûcs A; Liszkay G
    Magy Onkol; 2011 Jun; 55(2):91-8. PubMed ID: 21655474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling.
    Mangili G; Petrone M; Gentile C; De Marzi P; Viganò R; Rabaiotti E
    Gynecol Oncol; 2008 Feb; 108(2):332-5. PubMed ID: 18083217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyridoxine as prophylactic therapy for palmar-plantar erythrodysesthesia associated with administration of pegylated liposomal doxorubicin (caelyx): a single-center experience.
    Rossi D; Catalano G
    Oncology; 2007; 73(3-4):277-8. PubMed ID: 18424894
    [No Abstract]   [Full Text] [Related]  

  • 14. The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia.
    Martschick A; Sehouli J; Patzelt A; Richter H; Jacobi U; Oskay-Ozcelik G; Sterry W; Lademann J
    Anticancer Res; 2009 Jun; 29(6):2307-13. PubMed ID: 19528496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma.
    Molpus KL; Anderson LB; Craig CL; Puleo JG
    Gynecol Oncol; 2004 May; 93(2):513-6. PubMed ID: 15099971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of palmar-plantar erythrodysesthesia in pretreated and unpretreated patients receiving pegylated liposomal doxorubicin.
    Miolo G; Baldo P; Bidoli E; Lombardi D; Scalone S; Sorio R; Veronesi A
    Tumori; 2009; 95(6):687-90. PubMed ID: 20210230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chemotherapy-induced acral erythema: a clinical and histopathologic study of 44 cases].
    Hueso L; Sanmartín O; Nagore E; Botella-Estrada R; Requena C; Llombart B; Serra-Guillén C; Alfaro-Rubio A; Guillén C
    Actas Dermosifiliogr; 2008 May; 99(4):281-90. PubMed ID: 18394404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy and cutaneous toxicities: implications for oncology nurses.
    Viale PH
    Semin Oncol Nurs; 2006 Aug; 22(3):144-51. PubMed ID: 16893743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies.
    Drake RD; Lin WM; King M; Farrar D; Miller DS; Coleman RL
    Gynecol Oncol; 2004 Aug; 94(2):320-4. PubMed ID: 15297168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent palmar-plantar erythrodysaesthesia following high-dose cytarabine treatment for acute lymphoblastic leukemia.
    Crawford JH; Eikelboom JW; McQuillan A
    Eur J Haematol; 2002; 69(5-6):315-7. PubMed ID: 12460237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.